Ipilimumab
Surgery Programmed
Fondazione Policlinico Universitario Agostino Gemelli IRCCSmonoclonal_antibodyPhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Surgery Programmed cohort.
Same molecule, other indications
Ipilimumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →